Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial

B. Lassman, Andrew; L. Pugh, Stephanie; J. C. Wang, Tony; Aldape, Kenneth; Gan, Hui; Preusser, Matthias; A. Vogelbaum, Michael; P. Sulman, Erik; Won, Minhee; Zhang, Peixin; Moazami, Golnaz; S. Macsai, Marian; R. Gilbert, Mark; Bain, Earle; Blot, Vincent; Ansell, Peter; Samanta, Suvajit; G. Kundu, Madan; S. Armstrong, Terri; S. Wefel, Jeffrey; Seidel, Clemens; De Vos, Filip; Hsu, Sigmund; F. Cardona, Andrés; Lombardi, Giuseppe; Bentsion, Dmitry; A. Peterson, Richard; Gedye, Craig; Bourg, Veronique; Wick, Antje; J. Curran, Walter; P. Mehta, Minesh

doi:10.1093/neuonc/noac173

Public

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial

Published in Neuro-Oncology • Jul 15, 2022

Authors:

Andrew B. Lassman

Stephanie L. Pugh

Tony J. C. Wang

Abstract

BACKGROUND: Approximately 50% of newly diagnosed glioblastomas (GBMs) harbor epidermal growth factor receptor gene amplification (EGFR-amp). Preclinical and early-phase clinical data suggested efficacy of depatuxizumab mafodotin (depatux-m), an antibody-drug conjugate comprised of a monoclonal antib...

Subject

Medicine

Hazard ratio

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!